Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFusion Antibodies Regulatory News (FAB)

Share Price Information for Fusion Antibodies (FAB)

Share Price is delayed by 15 minutes
Get Live Data
13.00    0.00 (0.00%)
Bid:
12.50
Ask:
13.50
Spread: 1.00 (8.00%)
Market Cap: £16.25m
FAB Live PriceLast checked at - London Stock Exchange

Intraday Fusion Antibodies Share Chart

Acquisition

18 Jun 2007 07:01

Fabian Romania Property Fund Ltd18 June 2007 18 June 2007 Fabian Romania Property Fund Limited ("Fabian Romania" or "Fabian") Fabian Romania acquires the Baneasa Business Center in north Bucharest fromImmoconsult for €23.9 million Fabian Romania is pleased to announce that it has entered into an agreement topurchase its seventh office project in central north Bucharest from ImmoconsultLeasinggesellschaft m.b.H, with a transaction value of €23.9 million. Oncerefinanced, Fabian Romania's net equity investment will be €5 million. Theannual rental income is approximately €1.85 million per annum. Since itsAdmission to AIM, Fabian Romania has entered into four investments committingapproximately €34 million of the funds raised. The Baneasa Business Center provides 9,600 square metres of lettable space andis fully let. It is located in the central business district of north Bucharestand has a highly visible and prominent 32 metre frontage to Bucaresti-PloiestiSt, which runs directly north to the International airport. The immediatevicinity is well serviced by the main transport systems of Bucharest, and iswithin one of the fastest growing development locations of the city for bothoffice and retail estates. The Bucaresti-Ploiesti highway leads directly fromthe city center to Ploiesti City and links to the main E60 road to Brasov andTransylvania. The building offers good flexibility, having been constructed in three phases ina "Z" shape. Phase 1 of the building comprises a ground floor plus seven levels,whilst phases 2 and 3 both provide ground floor and nine upper levels, all werebuilt to Class A specification. Overground and underground parking facilitiesprovide for 132 vehicles. The Baneasa Business Center is currently fully let to fourteen internationaltenants, including Wrigley, Colgate, Fresenius, Cargill and Volksbank. There area variety of reversionary leases at rents between €12 per square metre to €16per square metre, providing an annual rental income of approximately €1.85million per annum. Concurrent with signing the acquisition Fabian has concluded debt financing withthe vendor's parent company Investkredit, via an 80 per cent. facility, reducingthe net equity requirement of Fabian Romania to approximately €5 million. Thisis the fourth credit facility Fabian has agreed with Investkredit in Romania. Claudius Ferentz, Managing Director of Investkredit Romania, quoted "This isanother exciting acquisition for Fabian and we are very pleased to have againpartnered them in providing an excellent financial services in a competitiveenvironment". Investkredit used the same team as per previous Fabian transactions, whichincluded Salans advising on legal aspects and NNKP representing Fabian. Responsible for the acquisition, Mark Owen, Property Director of Fabian Capital,Fabian Romania's investment adviser said: "This is further exciting news from Fabian, with three transactions announcedover the last three weeks. This acquisition adds an exciting asset managementopportunity to the Fabian Romania portfolio and has been converted from thepipeline discussed with investors at AIM admission. Over the medium term weshall aim to renegotiate the tenants' leases as they come up for renewal tocreate added value. The building is extremely flexible in design and is able toprovide floor plates between 700-1000sqm for which there is a shortage in themarket. Our ability to purchase a building of this type clearly sets us apartfrom our competitors and enables us to diversify in a fast moving emergingmarket". The lead advisers on the transaction were Eurisko (property agent), WSP(technical adviser), NNKP (legal adviser), KPMG (financial and tax adviser) andBiris Goran (legal advisor to Immoconsult) For Comments: Fabian Romania:Mark Holdsworth +44 20 7499 9988 Nominated Adviser:Deloitte & Touche LLPJames Lewis +44 20 7936 3000 Broker:Shore Capital Stockbrokers LimitedDru Danford +44 20 7408 4090 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
2nd Jun 20267:00 amRNSExercise of options and total voting rights
11th May 20263:06 pmRNSHolding(s) in Company
11th May 202611:05 amRNSGrant of patent in Japan
5th May 20267:00 amRNSYear-end trading statement
30th Mar 20267:00 amRNSAntibody IP transfer agreement
17th Feb 202611:42 amRNSDirector/PDMR Shareholding
4th Feb 20263:27 pmRNSHolding(s) in Company
2nd Feb 202611:33 amRNSHolding(s) in Company
30th Jan 20265:00 pmRNSTotal Voting Rights
27th Jan 20267:05 amRNSIssue of Director Shares
27th Jan 20267:00 amRNSPlacing and Subscription to raise approx £1.4m
19th Dec 20257:00 amRNSUpdate on negotiations with NCI regarding OptiMAL
19th Dec 20257:00 amRNSUpdate on negotiations with NCI regarding OptiMAL
16th Dec 202511:04 amRNSLaunch of OptiMAL platform
11th Dec 20257:00 amRNS-RMammalian Display video
25th Nov 202512:11 pmRNSHolding(s) in Company
24th Nov 20257:00 amRNSHalf-year Financial Report
21st Nov 20257:00 amRNSNotice of Results
13th Nov 20257:00 amRNS-ROptiMAL Library video
3rd Nov 20257:00 amRNSOptiMAL® R&D Update
27th Oct 20253:38 pmRNSHolding(s) in Company
16th Oct 20251:31 pmRNSResult of AGM
16th Oct 20257:00 amRNSAGM statement and H1 trading update
8th Oct 20257:00 amRNSContract win
19th Sep 202512:58 pmRNSPosting of Annual Report & Notice of AGM
17th Sep 20257:00 amRNSOptiMAL R&D Update
8th Sep 20257:00 amRNS-RBelfast investor presentation
4th Sep 20257:00 amRNSFinal Results
28th Aug 20257:00 amRNSContract Win
27th Aug 20257:00 amRNSContract wins with existing client
26th Aug 20257:00 amRNS-RInvestor presentations
5th Aug 20257:00 amRNSGrant of U.S. Patent for OptiMAL
24th Jul 202510:56 amRNSIssue Notification: US Patent Update
11th Jul 20257:00 amRNSDirector/PDMR Shareholding
2nd Jun 20257:00 amRNSTotal Voting Rights
22nd May 20252:33 pmRNSUpdate on U.S. Patent for OptiMAL®
8th May 20257:00 amRNS-RInvestor presentation
7th May 20257:00 amRNSIssue of shares to non-executive directors
6th May 202510:53 amRNSDirector/PDMR Shareholding
6th May 202510:38 amRNSHolding(s) in Company
6th May 20257:00 amRNSTrading update
30th Apr 20255:00 pmRNSTotal Voting Rights
24th Apr 20257:00 amRNSApproval of grant funding
11th Apr 202510:40 amRNSHolding(s) in Company
10th Apr 202512:47 pmRNSHolding(s) in Company
7th Apr 202512:35 pmRNSResult of General Meeting
31st Mar 20255:00 pmRNSTotal Voting Rights
24th Mar 20254:38 pmRNSHolding(s) in Company
18th Mar 20257:00 amRNSPlacing to raise approximately £1.17 million
27th Feb 20257:00 amRNSContract win

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.